SUPPORT LINE

0300 111 1234

Message

EU e-Privacy Directive

This website uses cookies to manage authentication, navigation, and other functions. By using our website, you agree that we can place these types of cookies on your device.

View e-Privacy Directive Documents

You have declined cookies. This decision can be reversed.

Otsuka Submits Application to EMA

User Rating: 1 / 5

Star ActiveStar InactiveStar InactiveStar InactiveStar Inactive
 

January 2014

In late December 2013, Otsuka Pharmaceutical Co Ltd submitted an application to the European Medicines Agency (EMA) for marketing authorisation of tolvaptan for the treatment of ADPKD in Europe.

The EMA considers marketing application authorisations (MAA) at the monthly meeting of its Committee for Medicinal Products for Human Use (CHMP). It is understood that the process could take 6 months. We will let everyone know the outcome immediately.

 

PrintEmail

Latest Tweets

PKD Charity is a Member of

  • Visit Ciliopathy Alliance website
  • Visit PKD International website
  • Visit EURORDIS website
  • Visit the Genetic Alliance UK website
  • Visit The Information Standard website
  • National Voices Website
  • Rare Disease UK Website
  • Specialised Healthcare Alliance Website
  • FEDERG Website